1	First Phase 1b, single-center, age de-escalation trial of the P. falciparum
2	blood-stage malaria vaccine candidate RH5.1/Matrix-M <sup>™</sup> :
3	a delayed boost regimen induces high levels of functional antibodies
4	in 5-17 month old Tanzanian infants
5	
6	Sarah E. Silk <sup>1,2,3</sup> , Wilmina F. Kalinga <sup>4,#</sup> , Jo Salkeld <sup>1,2,3,#</sup> , Ivanny M. Mtaka <sup>4</sup> , Saumu Ahmed <sup>4</sup> , Florence
7	Milando <sup>4</sup> , Ababacar Diouf <sup>5</sup> , Caroline K. Bundi <sup>6,7</sup> , Neema Balige <sup>4</sup> , Omar Hassan <sup>4</sup> , Catherine G. Mkindi <sup>4</sup> ,
8	Stella Rwezaula <sup>8</sup> , Thabit Athumani <sup>4</sup> , Sarah Mswata <sup>4</sup> , Nasoro S. Lilolime <sup>4</sup> , Beatus Simon <sup>4</sup> , Hania Msami <sup>4</sup> ,
9	Mohamed Mohamed <sup>4</sup> , Damiano M. David <sup>4</sup> , Latipha Mohammed <sup>4</sup> , Gloria Nyaulingo <sup>4</sup> , Bakari Mwalimu <sup>4</sup> ,
10	Omary Juma <sup>4</sup> , Tunu G. Mwamlima <sup>4</sup> , Ibrahim A. Sasamalo <sup>4</sup> , Rose P. Mkumbange <sup>4</sup> , Janeth J. Kamage <sup>4</sup> ,
11	Jordan R. Barrett <sup>1,2,3</sup> , Lloyd D. W. King <sup>1,2,3</sup> , Mimi M. Hou <sup>1,2,3</sup> , David Pulido <sup>2</sup> , Cecilia Carnrot <sup>9</sup> , Alison M.
12	Lawrie <sup>2,10</sup> , Rachel E. Cowan <sup>1,2,3</sup> , Fay L. Nugent <sup>1,2</sup> , Rachel Roberts <sup>1,2,3</sup> , Jee-Sun Cho <sup>1,2,3</sup> , Carole A. Long <sup>5</sup> ,
13	Carolyn M. Nielsen <sup>1,2,3</sup> , Kazutoyo Miura <sup>5</sup> , Simon J. Draper <sup>1,2,3,10,*</sup> , Ally I. Olotu <sup>4,*</sup> , and Angela M.
14	Minassian <sup>1,2,3,10,*,†</sup> .
15	
16	<sup>1</sup> Department of Biochemistry, University of Oxford, Dorothy Crowfoot Hodgkin Building, Oxford, OX1 3QU, UK.
17	<sup>2</sup> Centre for Clinical Vaccinology and Tropical Medicine, Jenner Institute, University of Oxford, Old Road Campus,
18	Oxford, OX3 7LE, UK.
19	<sup>3</sup> Kavli Institute for Nanoscience Discovery, Dorothy Crowfoot Hodgkin Building, University of Oxford, Oxford,
20	OX1 3QU, UK.
21	<sup>4</sup> Interventions and Clinical Trials Department, Ifakara Health Institute, P.O. Box 74, Bagamoyo, Tanzania.
22	<sup>5</sup> Laboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
23	<sup>o</sup> Kenya Medical Research Institute (KEMRI) Centre for Geographic Medicine Coast, KEMRI-Wellcome Trust
24 25	Research Programme, Kilifi, Kenya.
25 26	<sup>8</sup> Muhimbili National Hospital, Dar os Salaam, Tanzania
20 27	<sup>9</sup> Novavay AB Kungsgatan 109 SE-753 18 Unpsala Sweden
28	<sup>10</sup> NIHR Oxford Biomedical Research Centre Oxford UK
29	*.* These authors contributed equally.
30	<sup>†</sup> Corresponding author: Angela M. Minassian (angela.minassian@bioch.ox.ac.uk).

Silk SE et al.

- 31 This research was funded in part by the UK Medical Research Council (MRC) [Grant number:
- 32 MR/P020593/1 and MR/K025554/1]. For the purpose of Open Access, the author has applied a CC BY
- 33 public copyright licence to any Author Accepted Manuscript (AAM) version arising from this
- 34 submission.

#### Silk SE *et al*.

#### 35 Abstract

#### 36 Background

37 RH5.1 is a soluble protein vaccine candidate for blood-stage *Plasmodium falciparum* malaria, previously 38 trialed in healthy UK adults in combination with  $ASO1_B$  adjuvant. Here, RH5.1 was formulated with 39 Matrix-M<sup>TM</sup> adjuvant to assess safety and immunogenicity in a malaria-endemic adult and pediatric 40 population for the first time.

#### 41 Methods

42 We conducted a Phase 1b, single-center, dose-escalation, age de-escalation, first-in-human trial of 43 RH5.1/Matrix-M<sup>™</sup> in Bagamovo, Tanzania. Healthy adults (18-45 years) and infants (5-17 months) were recruited to receive the RH5.1/Matrix-M<sup>™</sup> vaccine candidate in a variety of dosing regimens, including 44 45 monthly dosing (0-1-2 month) or delayed booster dosing (0-1-6 month) using a 10 µg dose of RH5.1, or delayed fractional booster dosing (0-1-6 month) with the first two doses of RH5.1 at 50 ug and the third 46 47 dose at 10 µg. All RH5.1 protein doses were formulated with 50 µg Matrix-M<sup>TM</sup> adjuvant. Primary 48 outcomes for vaccine safety included solicited and unsolicited adverse events after each vaccination, 49 along with any serious adverse events (SAEs) during the study period. Secondary outcome measures for 50 immunogenicity included the concentration and avidity of anti-RH5.1 serum IgG antibodies by ELISA 51 and their percentage growth inhibition activity (GIA) in vitro against P. falciparum parasites using 52 purified IgG. All participants receiving at least one dose of vaccine were included in the primary analyses. 53 Findings Between 25th January 2021 and 15th April 2021 a total of 60 adults and infants were enrolled; 57 of these 54 55 completed the vaccination series, and 55 completed 22 months of follow-up post-third vaccination. 56 Vaccinations were well-tolerated across both age groups. There were five SAEs involving four infant 57 participants during the trial, none of which were deemed related to vaccination. RH5-specific T cell and 58 serum antibody responses were induced by vaccination. The anti-RH5 serum IgG responses were 59 significantly higher in the 5-17 month old infant groups as compared to adults. Serum antibody responses

Silk SE *et al*.

60	contracted over time post-third vaccination, but a similar hierarchy of responses across the age groups
61	was maintained after 22 months follow-up (674 days post-third vaccination). Vaccine-induced anti-RH5
62	antibodies showed in vitro GIA with comparable functional quality across all age groups and dosing
63	regimens. The highest anti-RH5 serum IgG responses were observed post-third vaccination in the 5-17
64	month old infants vaccinated with the 0-1-6 month delayed booster regimen using the 10 $\mu$ g dose of
65	RH5.1 (median 723 $\mu$ g/mL; range: 450-1436 $\mu$ g/mL), resulting in 100 % (11/11 infants) showing >60 %
66	GIA following dilution of total IgG to 2.5 mg/mL (median 88 %; range: 73-97 %).
67	Interpretation
68	The RH5.1/Matrix-M <sup>TM</sup> vaccine candidate shows an acceptable safety and reactogenicity profile and
69	highly promising antibody immunogenicity in 5-17 month old infants residing in a malaria-endemic area.
70	The 0-1-6 month delayed booster regimen in 5-17 month old infants induced the highest levels of
71	functional GIA reported to-date following human vaccination, with all infants achieving a level of GIA
72	previously associated with protective outcome against blood-stage P. falciparum challenge in non-human
73	primates. These data support onward efficacy assessment of this vaccine candidate against clinical
74	malaria in young African infants.
75	Funding
76	The European and Developing Countries Clinical Trials Partnership (EDCTP).
77	Trial Registration

78 ClinicalTrials.gov: NCT04318002.

#### Silk SE *et al*.

## 79 Introduction

Malaria is a leading global cause of disease and death despite decades of interventions. In 2022 there were 249 million cases and 608,000 deaths, with over 75% of deaths occurring in children under the age of five in sub-Saharan Africa<sup>1</sup>. Despite a welcome reduction in the global burden of disease between 2000 and 2015, this progress has since stalled and even reversed<sup>1</sup>. Malaria prevention services were significantly disrupted by the COVID-19 pandemic, and drug and insecticide resistance, along with conflict and climate change, together pose significant ongoing threats; highly effective vaccines thus remain urgently needed.

87 Encouragingly, two malaria vaccines targeting the sporozoite stage of *Plasmodium falciparum*,

88 RTS,S/AS01 (Mosquirix<sup>TM</sup>) and R21/Matrix-M<sup>TM</sup>, have now been recommended by the World Health

89 Organization (WHO); both vaccines have shown efficacy against clinical malaria in young African

90 infants in Phase 3 clinical trials <sup>2,3</sup>. However, higher efficacy vaccines with improved durability remain

91 needed, ideally without necessitating four doses. Moreover, efficacy against blood-stage infection with

92 pre-erythrocytic vaccines requires creation and maintenance of sterile immunity, a high hurdle. Thus,

addition of a complementary blood-stage vaccine strategy is attractive; such vaccines aim to prevent

94 invasion of erythrocytes by merozoites, leading to control and clearance of blood-stage parasitemia,

95 prevention of morbidity and reduced transmission <sup>4</sup>. Additionally, a multi-stage malaria vaccine,

96 consisting of partially effective anti-sporozoite and anti-merozoite components, provides a potential route

97 to achieving a highly effective intervention; whereby the blood-stage component would eliminate any

98 parasites that escaped the first (pre-erythrocytic) line of defense.

99

*P. falciparum* reticulocyte-binding protein homologue 5 (RH5) is the most advanced blood-stage vaccine
 candidate antigen. RH5 forms part of an invasion complex <sup>5,6</sup> and is both highly conserved and essential
 for invasion, where it mediates parasite binding to basigin on the erythrocyte surface <sup>7</sup>. *In vivo* protection

Silk SE *et al*.

103	induced by RH5 vaccination was first demonstrated in an Aotus monkey model using a stringent
104	heterologous <i>P. falciparum</i> challenge <sup>8</sup> . Importantly, this study demonstrated that <i>in vivo</i> protection
105	correlated with functional antibody activity, as measured by the <i>in vitro</i> growth inhibition activity (GIA)
106	assay, and it enabled protective threshold levels of GIA and anti-RH5 serum IgG antibody to be defined.
107	GIA was subsequently validated as a mechanistic immune correlate in Aotus by passive transfer of anti-
108	RH5 monoclonal antibody <sup>9</sup> .

109

110 The first RH5-based vaccine candidate to enter clinical trials was a viral-vectored formulation, consisting of the recombinant replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) and the attenuated 111 112 orthopoxvirus modified vaccinia virus Ankara (MVA). These were delivered to healthy UK adults in an 8 113 week prime-boost regimen (VAC057; ClinicalTrials.gov: NCT02181088). The viruses were safe and 114 well-tolerated and elicited a functional antibody response with cross-strain *in vitro* GIA<sup>10</sup>, although the level of GIA was below the *Aotus*-defined threshold of protection. However, given that another malaria 115 vaccine candidate based on the same ChAd63 prime-MVA boost platform <sup>11</sup> had previously been shown 116 117 to elicit 10-fold higher antibody levels in African infants (the target population for *P. falciparum* malaria 118 vaccines) as compared with UK adults, testing of the ChAd63-MVA RH5 candidate in a malaria-endemic 119 setting was warranted. A Phase 1b age de-escalation, dose escalation trial was therefore subsequently 120 undertaken in Tanzania (VAC070; NCT03435874). This showed that the same viral-vectored RH5 121 vaccine candidate induced 10-fold higher anti-RH5 IgG responses in Tanzanian 6-11 month old infants as 122 compared with UK adults, thus achieving the highest levels of functional GIA reported following human malaria vaccination at the time <sup>12</sup>. In an attempt to optimize antibody quantity further, a full-length RH5 123 124 soluble protein vaccine, called RH5.1, was subsequently developed <sup>13,14</sup> and initially trialled in UK adults 125 in a Phase 1/2a trial with GlaxoSmithKline's (GSK's) AS01<sub>B</sub> adjuvant (VAC063; NCT02927145). This 126 induced 10-fold higher antibody levels as compared to the viral-vectored RH5 in UK adults <sup>15</sup>. Anti-RH5 serum IgG responses in UK adults were also more durable when the third dose was delivered at 6 months 127

#### Silk SE et al.

128	and at one-fifth of the initial dose (a so-called "delayed fractionation" (DFx) regimen), as compared to
129	responses seen after three full (identical) doses given one month apart <sup>15</sup> .

130

131 Here we report a Phase 1b clinical trial in Tanzanian adults and infants [VAC080; NCT04318002] that was therefore designed to assess the safety and immunogenicity of the RH5.1 soluble protein vaccine 132 candidate, now formulated with Matrix-M<sup>™</sup> adjuvant from Novavax. Following first-in-human safety 133 134 assessment of this new formulation in adults, three different dosing regimens were assessed in the target infant population, 5-17 months of age (to align with delivery of R21/Matrix-M<sup>TM</sup> and RTS,S/AS01). This 135 136 trial was designed to assess whether the levels of anti-RH5 serum IgG and functional GIA associated with a protective outcome in the *Aotus* monkey -P. *falciparum* challenge model could also be achieved in 137 138 vaccinated African infants, and thereby inform decision-making on the progression of this RH5-based

139 vaccine candidate to Phase 2b field efficacy testing.

#### Silk SE et al.

### 140 **Results**

#### 141 Study recruitment and vaccinations

142 The VAC080 Phase 1b trial was conducted in the Bagamovo district of Tanzania. Malaria incidence in 143 the district was estimated to range from 539 cases per 1000-person years in higher transmission areas to 144 76 cases per 1000-person years in lower transmission areas in 2020<sup>16</sup>. The protocol recruitment plan was to recruit two groups of healthy adults (aged 18-45 years) and three groups of 5-17 month old infants 145 146 from Bagamoyo town, an area of relatively low malaria transmission within the district. The study was 147 also designed to include a fourth infant group with relatively higher malaria pre-exposure, to assess for 148 potential impact of prior malaria exposure on the immunogenicity of the RH5.1 /Matrix-M<sup>TM</sup> vaccine 149 candidate. 185 participants were screened and 60 of these (N=12 adults and N=48 infants) were enrolled 150 into the VAC080 Phase 1b trial (Figure 1). Prior to study start, an anti-parasite serological assay was 151 established to provide a relative assessment of previous malaria exposure in the 5-17 month old infant age 152 group. Serum IgG responses to parasite lysate of infants living in both urban (Dunda and Magomeni, 153 N=90) and rural (Yombo and Fukayosi, N=15) wards within Bagamoyo district were used to define 154 relative "low" versus "high" malaria pre-exposure thresholds relevant to this study population (Figure 155 **S1A**). Within the infant cohort, 156 were tested for anti-parasite lysate responses during screening 156 (Figure S1B), with N=36 recruited from those defined as relatively "low" prior malaria exposure and N=12 recruited from those defined as relatively "high" prior malaria exposure (Figure S1C). 157

158

Vaccinations began on 25th January 2021 and all 22 month post-third vaccination follow-up visits were completed by 27th July 2023. Group allocation was open label and non-randomized and enrolment proceeded in a dose escalation and age de-escalation fashion. Independent safety reviews were conducted by the Data Safety and Monitoring Board (DSMB) between every age de-escalation and dose-escalation step in the protocol. All vaccinations were administered via the intramuscular route in the deltoid and, in every case, the indicated dose of RH5.1 protein was formulated prior to injection with 50 µg Matrix-M<sup>TM</sup>

Silk SE et al.

165	adjuvant. Recruitment began with six adults in group "Adults 10M" who received 10 $\mu$ g RH5.1 at 0, 1
166	and 2 months (monthly regimen), followed by six adults in group "Adults DFx" who received 50 $\mu$ g
167	RH5.1 at 0 and 1 months and 10 $\mu$ g RH5.1 at 6 months (delayed-fractional regimen; DFx). Following a
168	safety review, the four groups of twelve 5-17 month old infants were enrolled. Those in group "Infants
169	10M" (monthly regimen) and group "Infants 10D" (10 µg RH5.1 at 0, 1 and 6 months; delayed regimen)
170	were recruited in parallel first, followed by group "Infants DFx", who received the DFx regimen. Finally
171	the group "High Infants DFx" was recruited as the relatively higher malaria pre-exposure cohort, and they
172	also received the DFx regimen. Two participants in the "High Infants DFx" cohort were recruited with
173	anti-parasite lysate IgG slightly below the serological threshold (Figure S1C); following a review they
174	continued to receive the remaining vaccinations and study visits as scheduled.
175	
176	The median age of adult participants was 23.5 years (range 20-30 years) and the median age of infant
177	participants was 12 months (range 5-17 months), with comparable ranges across the groups (Figure S2).
178	Similar numbers of males and females were enrolled across the infant age groups, however, although
179	there were no sex-based exclusion criteria, no adult female participants were screened or recruited. There
180	were three withdrawals during the vaccination period. Two participants withdrew after the first study
181	vaccination, one in "Adults 10M" and one in "High Infants DFx", and one participant in "Infants 10D"
182	withdrew after the second vaccination. One withdrawal was due to the participant moving out of the study
183	area and none were related to adverse experiences with study procedures. All other participants received
184	the study vaccinations as scheduled. Two infant participants died during the post-vaccination follow-up
185	period for reasons unrelated to the study or the study vaccinations as detailed below. All other participants
186	completed follow-up out to 22 months post-final vaccination.

187

Silk SE *et al*.

#### 188 **Outcomes and estimation**

### 189 **Reactogenicity and safety**

190 There were no safety concerns during the course of the trial. The majority of local solicited adverse events 191 (AEs) in both adults and infants were graded as mild to moderate in severity (Figure 2). Severe local 192 solicited AEs were reported in one adult and three infant participants. The most common local solicited 193 AE across all groups was swelling, reported after 18 % of vaccine doses (32/175 doses); this mainly 194 occurred after the second and third doses and was mild (11 %; 19/175 doses), moderate (7 %; 12/175) or 195 severe (1 %; 1/175) in graded severity. A slightly higher proportion of participants receiving the higher 50 196 µg dose of RH5.1 (those in groups "Adults DFx", "Infants DFx" and "High Infants DFx") experienced 197 local solicited AEs of moderate to severe grade (14 %; 12/88 doses) compared to the lower dose groups 198 (10 %; 9/87). Severe swelling and induration occurred in one adult participant from the lower dose group 199 ("Adults 10M") after the final vaccine administration; this resolved spontaneously within 7 days. All 200 other local AEs in adults resolved by 72 hours post-vaccine administration. In the two infant DFx regimen 201 groups, three infants developed severe and one developed moderate induration after receiving their final 202 delayed dose. The majority of local solicited AEs in infants resolved within 72 hours post-vaccination, 203 and all resolved by day 8.

204

205 The majority of systemic solicited AEs were mild in severity, and there were no severe systemic solicited 206 AEs reported (Figure 2). The most frequent systemic solicited AEs were mild subjective fever and mild 207 objective fever, reported after 18 % (31/175) and 7 % (12/175) of vaccinations, respectively, occurring 208 only in infants. One case of moderate severity subjective fever and one case of moderate severity 209 objective fever were reported in the higher dose infant groups after receiving the second study 210 vaccination. Vomiting, diarrhea, reduced oral intake and reduced activities were also experienced by 211 infants only and were all of mild severity. All systemic AEs reported by adult participants were mild in 212 severity, except for one participant who reported moderate grade headache on day one following both the

10 | P a g e

#### Silk SE et al.

	Sink SE et al.
213	first and second study vaccinations. In adults, most systemic solicited AEs resolved within 48 hours after
214	vaccination and in infants most systemic solicited AEs resolved within 72 hours of vaccine
215	administration. All systemic solicited AEs resolved by day 8.
216	
217	Unsolicited AEs deemed at least possibly related to study interventions were all of mild or moderate
218	severity (Figure S3). There was only one unsolicited AE in the adult groups – one participant reported an
219	episode of mild dizziness six days following the third study vaccination which resolved spontaneously on
220	the same day. There were five different unsolicited AEs in infants; all resolved within 8 days with the
221	exception of one participant who was diagnosed with a helminth infection which was deemed probably
222	related to vaccination due to the temporal association with study vaccination and lasted for 53 days. All
223	unsolicited AEs had resolved by the end of the study period.
224	
225	There were five serious adverse events (SAEs) involving four infant participants during the trial, none of
226	which were deemed related to vaccination (Figure S4). Two of the five SAEs had a fatal outcome: one
227	infant with stage IV neuroblastoma and one infant with acute respiratory failure secondary to herbal
228	intoxication. The independent trial DSMB was informed of both cases and determined there was no
229	relationship to study vaccinations. There were no AEs of special interest (AESIs) or suspected unexpected
230	serious adverse reactions (SUSARs) during the course of the trial.
231	
232	The most frequent laboratory abnormality identified in the 28-day post-vaccination period in adults was
233	lymphopenia, occurring in 17 % (1/6) of "Adults 10M" participants and 33 % (2/6) of "Adults DFx"

234 participants (**Figure S5**). All laboratory AEs occurring during this period in adults were mild in graded

severity and resolved by the end of the study period, apart from one participant who had mild

236 lymphopenia when they withdrew following their day 14 visit (post-first vaccination). The most frequent

237 laboratory abnormality identified in the 28-day post-vaccination period in infants was anemia, occurring

#### Silk SE et al.

238	in 58 % of participants (7/12) in the "Infants 10M", "Infants 10D" and "Infants DFx" groups, and in 42 %
239	(5/12) in the "High Infants DFx" group. The maximum severity of anemia was moderate grade and in all
240	cases had resolved by the final study visit (maximum duration 154 days). The majority of other laboratory
241	AEs occurring during this period in infants were mild to moderate and all had resolved by the final study
242	visit.
243	
244	There were three severe grade laboratory AEs in infants in the 28 days following vaccination (Figure S5).
245	One participant in the "High Infants DFx" group developed severe neutropenia at 7 days post-second
246	vaccination which was temporally associated with a diagnosis of eczema with superimposed bacterial
247	infection. This had improved to mild by day 14 and resolved completely by the third vaccination. One
248	participant in the "Infants 10D" group developed severe neutropenia at 7 days post-second vaccination
249	which resolved by day 14 and was temporally associated with a diagnosis of pneumonia. One participant
250	in the "High Infants DFx" group developed severe eosinophilia at 7 days post-third vaccination which
251	persisted at moderate grade until 28 days post-vaccination and had resolved by 84 days. There were no
252	symptoms suggestive of allergy and stool microscopy did not show any evidence of helminth infection.
253	This infant was well throughout this time period with no concerns apart from an isolated episode of fever
254	on day 22.
255	
256	All participants tested negative for malaria by microscopy at screening and were subsequently tested by
257	microscopy at the second and third vaccination visits and monthly thereafter. Two participants in the
258	"High Infants DFx" group (with higher prior malaria exposure) tested positive during study visits in the
259	follow-up period (at 4 and 12 months post-third vaccination); these participants were clinically well and
260	received anti-malarial treatment in the community. In addition, one participant in the "Infants DFx" group
261	tested positive for malaria outside of the study during chemotherapy for neuroblastoma (see above section
262	on SAEs).

Silk SE *et al*.

263

#### 264 Immunogenicity

265 The magnitude of the serum anti-RH5 IgG antibody response was measured over time by ELISA against 266 full-length RH5 (RH5.1) recombinant protein. Almost all participants showed background level responses 267 at baseline (data not shown); consistent with numerous other immuno-epidemiological data that suggest RH5 is not a dominant target of naturally-acquired malaria immunity <sup>10,17,18</sup>. Fourteen days following two 268 269 vaccinations (denoted "V2+14") of either 10 µg or 50 µg RH5.1 formulated with Matrix-M<sup>TM</sup> adjuvant, 270 responses were comparable across the two doses within the adult or infant cohorts (Figure 3A,B). 271 However, the magnitude of the antibody response showed a clear age-dependence, with significantly 272 higher responses observed in the 5-17 month old infants (Figure S6A); here the adult cohorts showed 273 median responses ranging from 38-52 µg/mL anti-RH5.1 IgG compared to the infant cohorts with ~4-5 274 fold-higher median responses ranging from 200-230 µg/mL. 275 276 Responses then declined over time and were significantly lower prior to the third vaccination (V3) in all 277 participants receiving the delayed or delayed-fractional boost at month 6, as compared to those receiving 278 a final boost at month 2 (Figure 3A,B). Subsequently, 14 days following the third dose (V3+14; day 70 for monthly cohorts and day 196 for delayed and delayed-fractional cohorts), significantly higher 279 280 responses (~2-3-fold) were maintained in the 5-17 month old infants, as compared to adults, regardless of 281 vaccination with either the monthly or DFx regimen (Figure S6B). Here, within the adult groups, 282 responses were moderately but significantly higher at V3+14 in those receiving the DFx as compared to 283 10M regimen, with median responses of 138  $\mu$ g/mL and 81  $\mu$ g/mL, respectively (Figure 3A). In contrast, 284 responses at V3+14 in the 5-17 month old infants receiving these same two regimens were comparable, 285 with median responses at  $\sim 290 \,\mu \text{g/mL}$  (Figure 3B). There was also no difference in the serum anti-RH5

286 IgG response at any time-point between the two infant cohorts who received the same DFx regimen, but

287 who differed in baseline malaria pre-exposure status (Figure 3C). However, in contrast, the infants

#### Silk SE et al.

288	receiving the 10D regimen showed significantly higher responses, reaching a median of 723 $\mu$ g/mL, with
289	all infants in this group showing anti-RH5 serum IgG responses at the V3+14 time-point above the level
290	associated with protection against <i>P. falciparum</i> blood-stage challenge in <i>Aotus</i> monkeys <sup>8</sup> (Figure 3B).
291	
292	To further explore immune responses following the third vaccination, we also assessed the avidity of the
293	anti-RH5 serum IgG response and the induction of RH5-specific IFN-7 T cell responses. Here, delayed
294	and DFx boosting, as opposed to monthly boosting, were both associated with significantly more avid
295	anti-RH5 IgG responses in adults and infants (Figure S7). In contrast, the anti-RH5 IFN- $\gamma$ T cell
296	response, as assessed by <i>ex-vivo</i> ELISpot assay <sup>15</sup> , was comparable across all groups, regardless of age or
297	vaccination regimen (Figure S8).
298	
299	Anti-RH5 serum IgG antibody responses subsequently declined over time (Figure S6C), but a similar
300	pattern of immunogenicity to the peak response was maintained at ~1 year post-third vaccination
301	(V3+309), although no significant differences were observed at $\sim$ 2 years (V3+674) between the monthly
302	and DFx regimens within the adult and infant cohorts (Figure 3A,B). The highest responses were
303	maintained at V3+674 in the Infants 10D cohort, with a median of 65 $\mu$ g/mL; these were significantly
304	higher than those in the Infants 10M cohort with median of 16 $\mu$ g/mL ( <b>Figure 3B</b> ).
305	
306	Serum samples were next analyzed for <i>in vitro</i> functional anti-parasitic activity at the GIA Reference
307	Center (NIAID/NIH). Purified total IgG was normalized to a starting concentration of 10 mg/mL and
308	tested against P. falciparum (3D7 clone) parasites using the standardized single-cycle GIA assay.
309	Samples at baseline (pre-vaccination) were negligible (<20 % GIA), with a single exception of one adult
310	who had 58 % GIA (Figure 4A), however large increases in overall GIA were observed post-
311	RH5.1/Matrix-M <sup>TM</sup> vaccination (Figure 4B). Here, at the V3+14 time-point (14 days post-dose 3) and
312	using 10 mg/mL total IgG, median levels ranged from 83-87 % and 95-98 % GIA across the adult and

Silk SE et al.

313	infant groups, respectively. All total IgG samples with >40 % GIA at 10 mg/mL were subsequently
314	titrated using a 2-fold dilution series in the assay (Figure S9A). The overall levels of GIA mirrored the
315	previous serology, with infants overall showing higher levels of GIA as compared to adults and as
316	measured using 2.5 mg/mL total purified IgG. Moreover, the infants vaccinated with the 10D regimen
317	showed the highest levels of GIA, significantly outperforming the 10M and DFx regimens tested in the
318	other infant groups (Figure 4C). There were also no differences seen in the levels of GIA between the
319	two infant cohorts who differed in baseline malaria pre-exposure status and received the same DFx
320	regimen (Figure 4D).
321	
322	The GIA showed a strong relationship to the concentration of RH5.1-specific IgG present in the total IgG
323	used in the assay and as measured by ELISA (Figure 4E). The concentration of RH5.1-specific
324	polyclonal IgG required to give 50 % GIA ( $EC_{50}$ ) was highly comparable across all the groups (regardless
325	of age, vaccine regimen and malaria pre-exposure status at baseline). Analysis across all groups combined
326	showed a GIA $EC_{50} = 14.3 \ \mu g/mL$ (95% CI: 13.4-15.2 $\mu g/mL$ ). This functional "quality" readout of the
327	RH5.1/Matrix-M <sup>TM</sup> vaccine candidate, i.e. the concentration of antigen-specific IgG required to achieve
328	50 % GIA, was consistent with our previously reported data following vaccination of healthy volunteers
329	in the UK or Tanzania with viral-vectored RH5 or RH5.1/AS01 <sub>B</sub> $^{10,12,15}$ (Figure S9B).
330	
331	We previously reported an association between the in vitro GIA assay and in vivo protection outcome
332	following RH5 vaccination and P. falciparum blood-stage challenge in Aotus monkeys, with protected

animals showing >60 % GIA at 2.5 mg/mL purified IgG<sup>8,9</sup>. A similar association was observed in a

334 controlled human malaria infection (CHMI) trial in healthy UK adults vaccinated with RH5.1/AS01<sub>B</sub>,

although this threshold level of GIA was not reached in that study <sup>15</sup>. Notably, in the VAC080 trial, all

four groups of vaccinated infants showed median levels of GIA at 2.5 mg/mL total IgG over the level of

337 60 % GIA (Figure S10A). The Infants 10D group showed the highest median level of GIA at 88 % with

Silk SE *et al*.

- all participants (11/11) above the 60 % GIA target threshold at day 14 following the third vaccination
- 339 (Figure 4C). This level of GIA is the highest level of functional GIA achieved following human
- 340 vaccination to date (**Figure S10B**).

Silk SE *et al*.

## 341 Discussion

Here we report a dose-escalation, age de-escalation, first-in-human clinical trial of the RH5.1/Matrix-M<sup>TM</sup> 342 343 vaccine candidate, assessed in a malaria-endemic population. These data in healthy Tanzanian adults and 344 5-17 month old infants show that this adjuvanted protein subunit vaccine formulation has a favorable 345 safety and reactogenicity profile, highly comparable to data from Phase 1b malaria vaccine trials using the R21 immunogen formulated with the same Matrix-M<sup>TM</sup> adjuvant <sup>19,20</sup>. Independent review concluded 346 347 none of the five SAEs (involving four infant participants) that occurred during the trial, including two 348 with fatal outcomes, were related to vaccination (see Supplementary Information). These occurred 349 against a similar backdrop child mortality rate (aged 1-5 years) of 26.5/1000 and infant mortality rate (aged 0-1 years) of 53.0/1000 in Bagamoyo District as last recorded in 2012<sup>21</sup>. Including this trial, safety 350 351 data have now been reported for 193 healthy volunteers (109 adults, 18 children and 66 infants) vaccinated with RH5-based vaccines <sup>10,12,15</sup>, all showing similar safety and tolerability profiles, whilst 352 Matrix-M<sup>TM</sup> adjuvant is now a component in vaccines for malaria and Covid-19 that are licensed for 353 human use <sup>3,22</sup>. On-going Phase 1/2 trials, including a Phase 2b efficacy trial in >200 infants 5-17 months 354 355 of age (VAC091; NCT05790889), continue to monitor the safety of RH5.1/Matrix-M<sup>TM</sup> vaccination. 356 The RH5.1/Matrix-M<sup>TM</sup> vaccine candidate was immunogenic for anti-RH5 IFN-γ T cell responses and 357 serum IgG antibody across all age groups and dosing regimens. The levels of peripheral T cell response 358 observed by ELISPOT assay were not dissimilar to those previously reported in UK adults immunized 359 with the RH5.1/AS01<sub>B</sub> formulation using the same dosing regimens  $^{15}$ . While the contribution of IFN- $\gamma$ -360 361 secreting T cells to RH5-mediated malaria immunity in humans remains unclear, it is likely that RH5-362 specific CD4<sup>+</sup> T cells are needed to help B cell responses. Indeed, previous work in UK adults has shown 363 RH5.1/AS01<sub>B</sub> can induce RH5-specific circulating T follicular helper (Tfh) cell responses and that these

364 correlate with both RH5-specific memory B cells and serum antibody <sup>23</sup>. Work remains on-going to

#### Silk SE *et al*.

365	investigate B and Tfh cell response phenotypes in the Tanzanian infant population vaccinated here with
366	RH5.1/Matrix-M <sup>TM</sup> .

367

368 Priming of Tanzanian adults with two doses of 10 or 50 µg RH5.1 formulated with 50 µg Matrix-M<sup>TM</sup> 369 led to similar anti-RH5 serum IgG responses two weeks after the second dose. Notably, however, 370 following the third dose, the 0-1-6 month DFx regimen induced significantly more avid and higher levels 371 of anti-RH5 serum IgG, as compared to the 0-1-2 monthly regimen; consistent with our previous 372 observations in UK adults vaccinated with the same dosing regimens of RH5.1 with AS01<sub>B</sub> adjuvant  $^{15}$ . 373 These serum IgG responses were better maintained over time in the DFx regimen vaccinees for at least 374  $\sim$ 1 year following the third dose, although responses declined by  $\sim$ 2 years. In line with this, we have also 375 reported enhanced circulating RH5-specific memory B cell responses in adults vaccinated with the DFx 376 (as opposed to monthly) dosing regimen, along with a higher frequency of RH5-specific (and putatively 377 long-lived) plasma cells in the bone marrow that correlated strongly with the serum anti-RH5 IgG response 24,25. 378

379

380 Interestingly, these observations in adult vaccinees were only partly replicated in the 5-17 month old 381 infants. Responses were again similar two weeks after the second vaccination, regardless of RH5.1 382 protein priming dose, however, following the third vaccination the monthly and DFx regimens performed 383 comparably, whereas significantly higher anti-RH5 serum IgG responses were induced in those infants 384 receiving a delayed, but not fractionated dose, of RH5.1 protein at 6 months. The underlying reasons for this improvement with the delayed, as opposed to DFx, regimen remain to be determined, although 385 386 circulating levels of vaccine-specific antibody may affect vaccine responsiveness <sup>26</sup> and this cohort 387 primed twice with 10 µg RH5.1 with Matrix-M<sup>TM</sup> showed lower anti-RH5 serum IgG responses at the 388 time of third vaccination (month 6) as compared to those in the DFx regimen group who were primed 389 twice with a higher 50 µg RH5.1 dose. In line with our observations here, trials of RTS,S/AS01 showed

Silk SE *et al*.

390	improved outcome measures with a DFx regimen, as opposed to 0-1-2 monthly dosing, in healthy US
391	adults <sup>27</sup> , however no improvement in field efficacy when tested in 5-17 month old infants <sup>28</sup> . Notably,
392	these DFx regimens tested with RTS,S/AS01 fractionated the dose of adjuvant and antigen, unlike our
393	trials where a fractionated dose of antigen is delivered in a full dose of adjuvant. Nevertheless, our data
394	suggest a delayed boosting, as opposed to DFx, regimen may be more optimal in this younger age group
395	and this warrants further investigation.

396

397 Regardless of vaccination regimen, peak anti-RH5 serum IgG responses in the 5-17 month old infants 398 were significantly higher than those induced in adults – a phenomenon now consistently observed with 399 numerous other malaria subunit vaccine candidates including viral-vectored and recombinant antigen-inadjuvant formulations such as R21/Matrix-M<sup>TM 11,12,19,29,30</sup>. These data bode well for future assessment of 400 401 multi-stage malaria vaccine strategies, whereby a blood-stage RH5 component could be trialed in 402 combination with the licensed pre-erythrocytic vaccines. The very high levels of anti-RH5 serum IgG 403 induced in the 5-17 month old infants translated into the highest levels of functional GIA observed in 404 human vaccinees to-date. Indeed, overall GIA largely mirrored the serological responses, and all infants 405 vaccinated with the 0-1-6 month delayed boost regimen (who averaged ~700 µg/mL RH5-specific IgG at 406 the peak of the response) exceeded the threshold level of *in vitro* GIA that our work has previously 407 associated with a protective outcome in Aotus monkeys challenged with blood-stage P. falciparum<sup>8,9</sup>. 408 Importantly, this GIA threshold was also reached in 75% of infants vaccinated with the 0-1-2 month 409 regimen, suggesting RH5 vaccination could be aligned with the current delivery schedule for the primary 410 series of RTS,S/AS01 and/or R21/Matrix-M<sup>TM</sup>. The functional quality of serum antibody induced by 411 RH5.1/Matrix-M<sup>TM</sup> (i.e. GIA per µg anti-RH5 IgG) was also highly similar across all age groups and 412 vaccination regimens tested here, and also highly similar to that reported in all previous clinical trials of 413 vaccine candidates based on the full-length RH5 molecule <sup>10,12,15</sup>. Consistent with previous observations using RH5.1/AS01<sub>B</sub> in UK adults <sup>15,25</sup>, all the delayed booster regimens tested here in adults and infants 414

Silk SE *et al*.

415	also showed improvement in the avidity of anti-RH5 serum IgG, however, this did not impact the
416	functional quality of these IgG in the assay of GIA. These observations have now been explained by
417	analysis of anti-RH5 human mAbs that showed delayed boosting leads to improvement in the anti-RH5
418	antibody dissociation rates, but not in the antibody association rates which are strongly correlated with
419	GIA potency <sup>31</sup> .

420

421 Previous work on historical blood-stage vaccine candidates targeting the AMA1 antigen suggested that 422 naturally-occurring anti-malarial antibody responses could interfere with vaccine-induced IgG<sup>32</sup>, whilst 423 other studies have suggested such antibodies may interact additively or synergistically with anti-RH5 IgG in terms of GIA<sup>33</sup>. We therefore also assessed the DFx regimen in 5-17 month old infants who had 424 425 experienced relatively higher levels of malaria exposure prior to study recruitment. Our data indicated no 426 apparent impact of these anti-malarial responses on RH5.1/Matrix-M<sup>TM</sup> immunogenicity or functional 427 GIA. Whether much higher levels of existing anti-malarial natural immunity at the time of RH5 vaccine 428 priming may enhance or interfere with vaccine outcomes now remains to be determined in larger field 429 trials at sites of higher malaria endemicity.

430

The main limitations of this trial were the relatively small numbers of participants recruited from an area of low to moderate malaria transmission, and that in the adult groups only males volunteered to participate. Nonetheless, the very high levels of GIA achieved in this trial indicate that a 0-1-6 month delayed boost regimen with RH5.1/Matrix-M<sup>TM</sup> may protect the 5-17 month old target population against blood-stage *P. falciparum* malaria. In light of this, the RH5.1/Matrix-M<sup>TM</sup> vaccine candidate has since progressed to a Phase 2b field efficacy trial in Burkina Faso (VAC091; NCT05790889) to assess efficacy against clinical malaria following monthly or delayed boost vaccination.

#### Silk SE *et al*.

#### 438 Methods

#### 439 Study Design

- 440 The VAC080 trial was an open-label, age de-escalation, dose-escalation study, conducted according to the
- 441 principles of the current revision of the Declaration of Helsinki 2013 and in full conformity with the ICH
- 442 guidelines for Good Clinical Practice (GCP). It was approved by the Oxford Tropical Research Ethics
- 443 Committee in the UK (reference 9-20), and the following authorities in Tanzania: the Ifakara Health
- 444 Institute Institutional Review Board (reference 49-2020), the National Institute for Medical Research, the
- 445 National Health Research Ethics Sub-Committee and the Tanzania Medicines and Medical Devices
- 446 Authority (reference TMDA0020/CTR/0006/01). The VAC080 trial was registered on ClinicalTrials.gov
- 447 (NCT04318002). The study was conducted at Ifakara Health Institute Clinical Trial Facility, Bagamoyo
- 448 Research and Training Centre, Tanzania.

449

- 450 We report here the safety, reactogenicity and immunogenicity profile of vaccination with the RH5.1
- 451 protein <sup>14</sup> given with 50 μg Matrix-M<sup>TM</sup> adjuvant (Novavax) in monthly, delayed and delayed-fractional
- 452 regimens up until 674 days (22 months) post-final study vaccination. The Consolidated Standards of
- 453 Reporting Trials (CONSORT) guidelines were followed.

454

#### 455 **Participants**

Healthy adults (18-45 years) and infants (5-17 months) residing in Bagamoyo District, Tanzania, with a negative malaria blood film at screening, were eligible for inclusion in the study. Enrolment was into six groups (two adult and four infant groups) according to age, timing of enrolment and malaria pre-exposure status (infants only). A full list of inclusion and exclusion criteria are listed in the study protocol which is included within the Supplementary Appendix.

461

Silk SE *et al*.

462	Each participant (or guardian) signed or thumb-printed an informed consent form at the in-person
463	screening visit and consent was verified before each vaccination. The independent DSMB periodically
464	reviewed the study progress and safety data according to a safety review schedule, including prior to each
465	age de-escalation or dose escalation step.
466	
467	Procedures
468	Safety Analysis
469	Following each vaccination, each participant was visited at home on days 1 (infants only), 3, 4, 5 and 6 by
470	a community health worker for assessment and any solicited and unsolicited AEs were recorded. At days
471	1 (adults only), 2, 7, 14 and 28 post-vaccination, participants were seen at the clinical research facility. In
472	addition, participants attended the facility for follow-up on days 84, 112, 309 and 674 post-third
473	vaccination. Solicited AEs were collected at visits up to 7 days post-vaccination and unsolicited AEs were
474	collected at visits up to 28 days post-vaccination. SAEs were collected at all visits. Observations (heart
475	rate, temperature and blood pressure measurements) were taken at the clinic visits from the day of
476	vaccination until day 84 post-third vaccination. Blood tests for exploratory immunology were taken at all
477	visits except those occurring 2 days after each vaccination and 7 days after the first vaccination. Blood
478	samples for safety (full blood count, alanine aminotransferase and creatinine) were carried out at
479	screening and at all clinic visits except those occurring on days 1-2 post-vaccination and on 28 days post-
480	second vaccination for the delayed regimen groups.
481	
482	Solicited AEs were defined as being at least possibly related to vaccination. The likely causality and
483	grading of unsolicited AEs and SAEs were assessed as described in the protocol. Unsolicited AEs were

485

484

classified according to MedDRA (version 26.0).

Silk SE et al.

486	Outcomes
487	Primary outcome measures for vaccine safety included solicited and unsolicited AEs after each
488	vaccination, along with any SAEs during the study period. The primary outcome analysis was conducted
489	on the safety analysis population which included participants who received at least the first dose of
490	vaccine in the study. Solicited AEs were collected for seven days after each study vaccination and the
491	maximum severity reported for each solicited systemic and local AE by each participant after each
492	vaccination was summarized by group. Unsolicited AEs were collected for 28 days after each study
493	vaccination and those deemed at least possibly related to study vaccination are reported. SAEs were
494	collected for the entire study period and all SAEs, regardless of causality, are reported.
495	
496	The secondary outcome measures for immunogenicity were the concentration and avidity of anti-RH5.1
497	serum IgG antibodies by ELISA and their percentage GIA in vitro using purified IgG, as well as cellular
498	immunogenicity to RH5.1 as measured by ELISPOT and/or (reported elsewhere) flow cytometry.
499	
500	Exploratory outcome measures included the assessment of the frequency of RH5-specific plasma cells
501	from bone marrow aspirates at baseline and 4 weeks post-third vaccinations, reported elsewhere <sup>24</sup> .
502	
503	Vaccines
504	The design, production and preclinical testing of RH5.1 has been reported previously in detail <sup>13,14</sup> .
505	Briefly, RH5.1 is a soluble protein immunogen based on the full-length P. falciparum reticulocyte-
506	binding protein homologue 5 (RH5). The protein is produced by secretion from Drosophila melanogaster
507	Schneider-2 cells. RH5.1 was developed at the University of Oxford and an initial batch produced to
508	Good Manufacturing Practice (GMP) by the Clinical Biomanufacturing Facility in Oxford.
509	

#### Silk SE et al.

510	Matrix-M <sup>TM</sup> adjuvant was manufactured by Novavax AB (Uppsala, Sweden). It is a potent, saponin-based
511	adjuvant and comprises of partially-purified extracts of the bark of the Quillaja saponaria Molina tree,
512	phosphatidylcholine and cholesterol. Matrix-M <sup>TM</sup> has demonstrated a favorable safety profile, as well as
513	enhancement of cellular and humoral immune responses to a range of vaccine candidates and is licensed
514	for human use in other malaria and Covid-19 vaccines <sup>3,22</sup> .
515	
516	Peripheral Blood Mononuclear Cell (PBMC), Plasma and Serum Preparation
517	Blood samples were collected into lithium heparin-treated vacutainer blood collection systems (Becton
518	Dickinson, UK). PBMC were isolated and used within 6 h in fresh assays as previously described <sup>34</sup> .
519	Excess cells were frozen in fetal calf serum (FCS) containing 10 % dimethyl sulfoxide and stored in
520	liquid nitrogen. Plasma samples were stored at -80 °C. For serum preparation, using untreated
521	vacutainers, blood samples were stored at room temperature and then the clotted blood was centrifuged
522	for 5 min (1000 xg). Serum was stored at -80 °C.
523	
524	Anti-parasite Lysate ELISA
525	Serum antibody levels to parasite lysate were assessed by standardized ELISA methodology previously
526	described <sup>12,16,35</sup> . Schizont extract from <i>P. falciparum</i> (3D7 clone) parasites produced by the GIA
527	Reference Laboratory, NIAID, NIH, was adsorbed overnight at 4 °C to 96 well NUNC-Immuno Maxisorp
528	plates (Thermo Fisher Scientific) at an equivalent of $5x10^2$ parasites per $\mu$ L. Test sera were diluted in 1 %
529	milk in Dulbecco's phosphate buffered saline (DPBS) and added in triplicate to plates following blocking
530	with 5 % milk in DPBS (Sigma). A reference standard and internal control samples from a pool of $N=34$
531	"high" malaria pre-exposed serum samples, from the Bagamoyo Clinical Trial Facility-Ifakara Health
532	Institute (BCTF-IHI) Biobank, plus blank wells, were included. Use of these samples received ethical
533	approval from the Ifakara Health Institute Institutional Review Board (IHI/IRB/No: 49-2020). Bound

antibodies were detected using goat anti-human IgG conjugated to alkaline phosphatase (Sigma),

### Silk SE et al.

535	developed using 4-nitrophenyl phosphate disodium salt hexahydrate (Sigma) and absorbance at 405 nm
536	(OD <sub>405</sub> ) was determined on a BioTek Elx808 reader with Gen5 software. Antibody units were assigned
537	using the reciprocal dilution of the standard giving an optical density of 1.0 at $OD_{405}$ . The standard curve
538	and Gen5 software v3.04 (Agilent) were then used to convert the $OD_{405}$ of test samples to arbitrary units
539	(AU). "Low" and "high" malaria pre-exposure thresholds were first defined at <25 <sup>th</sup> percentile (20 AU)
540	and >75% percentile (85 AU) of all N=105 population test samples. However, due to a large number of
541	screening failures making recruitment difficult these were redefined as <75% percentile (71 AU) from
542	"urban" wards, Magomeni and Dunda, and >60% percentile (140 AU) from "rural" wards, Fukayosi and
543	Yombo, within Bagamoyo district. These criteria maintained a clear difference in anti-malarial antibody
544	levels between the two cohorts.
545	
546	RH5 ELISA
547	Anti-RH5 total IgG ELISAs were performed against full-length RH5 protein (RH5.1) using standardized
548	methodology as previously described $^{10,12,15}$ . The reciprocal of the test sample dilution giving an $OD_{405}$ of
549	1.0 in the standardized assay was used to assign an ELISA unit value of the standard. A standard curve
550	and Gen5 ELISA software v3.04 (BioTek, UK) were used to convert the $OD_{405}$ of individual test samples
551	into AU. These responses in AU are reported in $\mu$ g/mL following generation of a conversion factor by
552	calibration-free concentration analysis as reported previously <sup>10</sup> .
553	
554	Avidity ELISA
555	Anti-RH5.1 IgG antibody avidity was assessed by sodium thiocyanate (NaSCN)-displacement ELISA
556	using previously described methodology <sup>10,15</sup> . The concentration of NaSCN required to reduce the
557	$OD_{405}$ to 50% of that without NaSCN was used as a measure of avidity (IC <sub>50</sub> ).

558

Silk SE et al.

JJ7 Assay of Growth Innibition Activity (Gr	559	9 Assav of	Growth	Inhibition	Activity	(GIA	)
---	-----	------------	--------	------------	----------	------	---

560	Standardized assays were performed by the GIA Reference Center, NIH, USA, using previously
561	described methodology <sup>36</sup> . Each sample was tested in three independent replication assays using three
562	different batches of red blood cells (RBC), and the median of these three results was used to generate the
563	final dataset as per previously reported RH5 vaccine trials and methodology <sup>12,15,37</sup> . For each assay, in
564	brief, protein G purified IgG samples were incubated with RBC infected with synchronized P. falciparum
565	3D7 clone parasites in a final volume of 40 $\mu$ L for 40 h at 37 °C, and the final parasitemia in each well
566	was quantified by biochemical determination of parasite lactate dehydrogenase. All purified IgG samples
567	were tested initially at 10 mg/mL final test well concentration. For samples with >40 % GIA at 10
568	mg/mL, a dilution series was tested and used to determine the concentration that gave 50 % GIA (EC $_{50}$ ).
569	
570	IFN-y ELISPOT
571	Fresh PBMC were used in all assays using a previously described protocol <sup>10,12,15</sup> . Spots were counted
572	using an ELISPOT counter (Autoimmun Diagnostika (AID), Germany). Results are expressed as IFN-y
573	spot-forming units (SFU) per million PBMC with unstimulated control well responses subtracted from
574	peptide-stimulated well measurements.
575	
576	Statistical Analysis
577	Data were analyzed using GraphPad Prism version 10.1 for Windows (GraphPad Software Inc.,
578	California, USA). All tests used were two-tailed and are described in the text. A value of $P < 0.05$ was

579 considered significant.

Silk SE et al.

#### 580 Author Contributions

- 581 Conceived and performed the experiments: SES, WFK, JS, IMM, FM, AD, CKB, NB, OH, CGM, SR, SM,
- 582 NSL, BS, HM, MM, DMD, LM, GN, BM, OJ, TGM, IAS, RPM, JJK, JRB, LDWK, MMH, DP, CAL,
- 583 CMN, KM, SJD, AIO, AMM.
- 584 Analyzed the data: SES, WFK, JS, TA, KM, SJD, AIO, AMM.
- 585 Project Management: SA, CC, AML, REC, FLN, RR, J-SC.
- 586 Wrote the paper: SES, JS, SJD, AMM.

#### 587 Acknowledgments

588 The authors are grateful to Julie Furze, Jing Jin, Daniela Tomescu, Rebecca Ashfield, Kate Skinner,

589 Susanne Hodgson, Cheryl Turner, Jack Quaddy, Subarna Sriskantharajah and Hilary Vitkus for assistance

and Sally Pelling-Deeves for arranging contracts (University of Oxford); Richard Tarrant, Helena

591 Parracho, Robert Smith and Catherine Green (Clinical Biomanufacturing Facility, University of Oxford);

592 Jenny Reimer (Novavax); the independent DSMB for their insightful safety oversight (Brian Angus,

Karim Manji, Roma Chilengi, Kwaku Poke Asante, William Macharia and Greg Fegan); and all the study
 participants.

595

596 This work was funded in part by the European and Developing Countries Clinical Trials Partnership

597 (EDCTP) Multi-Stage Malaria Vaccine Consortium (MMVC) [RIA2016V-1649-MMVC]; an African

598 Research Leader Award to AIO from the UK Medical Research Council (MRC) [MR/P020593/1], this

award was jointly funded by the UK MRC and the UK Department for International Development (DFID)

600 under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the

European Union; the UK MRC [MR/K025554/1]; the National Institute for Health and Care Research

602 (NIHR) Oxford Biomedical Research Centre (BRC), the views expressed are those of the authors and not

necessarily those of the NHS, the NIHR, or the Department of Health; the GIA work was supported by

Silk SE *et al*.

604	the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID) and
605	by an Interagency Agreement (AID-GH-T-15-00001) between the United States Agency for International
606	Development (USAID) Malaria Vaccine Development Program (MVDP) and NIAID. The findings and
607	conclusions are those of the authors and do not necessarily represent the official position of USAID.
608	CMN held a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellowship [209200/Z/17/Z]. SJD is a
609	Jenner Investigator.
610	
611	Conflict of Interest Statement
612	LDWK and SJD are named inventors on patent applications relating to RH5 malaria vaccines. AMM has
613	an immediate family member who is an inventor on patent applications relating to RH5 malaria vaccines.
614	All other authors have declared that no conflict of interest exists.
615	
616	Data and Matarials Availability

# 616 **Data and Materials Availability**

617 Requests for materials should be addressed to the corresponding authors.

Silk SE et al.

# 618 **References**

619	1. World Health O. World malaria report 2023. Geneva: World Health Organization; 2023.
620	2. Rts SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in
621	infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet
622	2015; <b>386</b> (9988): 31-45.
623	3. Datoo MS, Dicko A, Tinto H, et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-
624	M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 2024; <b>403</b> (10426):
625	533-44.
626	4. Draper SJ, Sack BK, King CR, et al. Malaria Vaccines: Recent Advances and New Horizons. <i>Cell</i>
627	Host Microbe 2018: <b>24</b> (1): 43-56.
628	5. Scally SW, Triglia T, Evelyn C, et al. PCRCR complex is essential for invasion of human
629	erythrocytes by Plasmodium falciparum. <i>Nature microbiology</i> 2022; 7(12): 2039-53.
630	6. Ragotte RJ, Higgins MK, Draper SJ. The RH5-CyRPA-Ripr Complex as a Malaria Vaccine
631	Target. Trends Parasitol 2020; <b>36</b> (6): 545-59.
632	7. Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a receptor essential for erythrocyte
633	invasion by Plasmodium falciparum. <i>Nature</i> 2011; <b>480</b> (7378): 534-7.
634	8. Douglas AD, Baldeviano GC, Lucas CM, et al. A PfRH5-Based Vaccine Is Efficacious against
635	Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys. Cell Host
636	Microbe 2015; <b>17</b> (1): 130-9.
637	9. Douglas AD, Baldeviano GC, Jin J, et al. A defined mechanistic correlate of protection against
638	Plasmodium falciparum malaria in non-human primates. Nat Commun 2019; <b>10</b> (1): 1953.
639	10. Payne RO, Silk SE, Elias SC, et al. Human vaccination against RH5 induces neutralizing
640	antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight 2017; 2(21): 96381.
641	11. Bliss CM, Drammeh A, Bowyer G, et al. Viral Vector Malaria Vaccines Induce High-Level T
642	Cell and Antibody Responses in West African Children and Infants. Mol Ther 2017; 25(2): 547-59.
643	12. Silk SE, Kalinga WF, Mtaka IM, et al. Superior antibody immunogenicity of a viral-vectored
644	RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults. Med 2023; 4(10): 668-86.
645	13. Hjerrild KA, Jin J, Wright KE, et al. Production of full-length soluble Plasmodium falciparum
646	RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system. Sci Rep 2016;
647	<b>6</b> : 30357.
648	14. Jin J, Tarrant RD, Bolam EJ, et al. Production, quality control, stability, and potency of cGMP-
649	produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells. NPJ Vaccines
650	2018; <b>3</b> : 32.
651	15. Minassian AM, Silk SE, Barrett JR, et al. Reduced blood-stage malaria growth and immune
652	correlates in humans following RH5 vaccination. <i>Med</i> 2021; <b>2</b> (6): 701-19.
653	16. Mwamlima TG, Mwakasungula SM, Mkindi CG, et al. Understanding the role of serological and
654	clinical data on assessing the dynamic of malaria transmission: a case study of Bagamoyo district,
655	Tanzania. Pan Afr Med J 2022; <b>43</b> : 60.
656	17. Douglas AD, Williams AR, Illingworth JJ, et al. The blood-stage malaria antigen PfRH5 is
657	susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2011; 2: 601.
658	18. Osier FH, Mackinnon MJ, Crosnier C, et al. New antigens for a multicomponent blood-stage
659	malaria vaccine. Sci Transl Med 2014; 6(247): 247ra102.
660	19. Sang S, Datoo M, Otieno E, et al. Safety and immunogenicity of varied doses of R21/Matrix-M?
661	vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children,
662	and infants in Kilifi-Kenya [version 1; peer review: awaiting peer review]. Wellcome open research 2023;
663	8(450).

Silk SE *et al*.

664 20. Venkatraman N, Tiono AB, Bowyer G, et al. Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and 665 666 Burkinabe volunteers. medRxiv 2019: 19009282. 667 21. https://www.nbs.go.tz/nbs/takwimu/census2012/Mortality and Health Monograph.pdf. Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 668 22. 669 Vaccine. N Engl J Med 2021; 385(13): 1172-83. 670 23. Nielsen CM, Ogbe A, Pedroza-Pacheco I, et al. Protein/AS01B vaccination elicits stronger, more 671 Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. Cell Rep Med 2021; 2(3): 100207. 672 673 Barrett JR, Silk SE, Mkindi CG, et al. Analyses of human vaccine-specific circulating and bone 24. 674 marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage 675 malaria antigens. Front Immunol 2023; 14: 1193079. 676 Nielsen CM, Barrett JR, Davis C, et al. Delayed boosting improves human antigen-specific Ig and 25. 677 B cell responses to the RH5.1/AS01B malaria vaccine. JCI Insight 2023; 8(2). McNamara HA, Idris AH, Sutton HJ, et al. Antibody Feedback Limits the Expansion of B Cell 678 26. 679 Responses to Malaria Vaccination but Drives Diversification of the Humoral Response. Cell Host 680 *Microbe* 2020; **28**(4): 572-85 e7. 681 Regules JA, Cicatelli SB, Bennett JW, et al. Fractional Third and Fourth Dose of RTS,S/AS01 27. 682 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and 683 Immunogenicity Study. J Infect Dis 2016; 214(5): 762-71. 684 Samuels AM, Ansong D, Kariuki SK, et al. Efficacy of RTS,S/AS01(E) malaria vaccine 28. 685 administered according to different full, fractional, and delayed third or early fourth dose regimens in 686 children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial. 687 Lancet Infect Dis 2022; 22(9): 1329-42. 688 29. Rts SCTP. Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after 689 vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS 690 Med 2014; 11(7): e1001685. 691 Leroux-Roels G, Leroux-Roels I, Clement F, et al. Evaluation of the immune response to 30. 692 RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naive 693 adults. Hum Vaccin Immunother 2014; 10(8): 2211-9. 694 Barrett JR, Pipini D, Wright ND, et al. Analysis of the Diverse Antigenic Landscape of the 31. 695 Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype. 696 bioRxiv 2023: 2023.10.04.560576. 697 Miura K, Perera S, Brockley S, et al. Non-apical membrane antigen 1 (AMA1) IgGs from Malian 32. 698 children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay. PLoS One 699 2011; **6**(6): e20947. 700 Willcox AC, Huber AS, Diouf A, et al. Antibodies from malaria-exposed Malians generally 33. 701 interact additively or synergistically with human vaccine-induced RH5 antibodies. *Cell Rep Med* 2021; 702 2(7): 100326. 703 34. Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia Clinical Evaluation of the Safety and 704 Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA 705 Vaccine Vectors. PLoS One 2012; 7(2): e31208. 706 35. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, Long CA. Development and 707 characterization of a standardized ELISA including a reference serum on each plate to detect antibodies 708 induced by experimental malaria vaccines. Vaccine 2008; 26(2): 193-200. 709 36. Malkin EM, Diemert DJ, McArthur JH, et al. Phase 1 clinical trial of apical membrane antigen 1: 710 an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 2005; 73(6): 3677-85. 711 37. Miura K, Diouf A, Fay MP, et al. Assessment of precision in growth inhibition assay (GIA) using 712 human anti-PfRH5 antibodies. Malar J 2023; 22(1): 159.

#### Silk SE et al.

## 713 Figure Legends

#### 714 **Figure 1: Trial profile.**

- 715 "Adults 10M" (adults aged 18-45 years) received 10 μg RH5.1 with 50 μg Matrix-M<sup>TM</sup> at 0, 1 and 2
- months. "Adults Delayed-Fractional [DFx]" (adults aged 18-45 years) received 50 µg RH5.1 with 50 µg
- 717 Matrix-M<sup>™</sup> at 0 and 1 months and 10 µg RH5.1 with 50 µg Matrix-M<sup>™</sup> at 6 months. "Infants 10M"
- (infants aged 5-17 months) received 10 µg RH5.1 with 50 µg Matrix-M<sup>TM</sup> at 0, 1 and 2 months. "Infants
- 10D" (infants aged 5-17 months) received 10 µg RH5.1 with 50 µg Matrix-M<sup>™</sup> at 0, 1 and 6
- months. "Infants DFx" (infants aged 5-17 months) received 50 µg RH5.1 with 50 µg Matrix-M<sup>™</sup> at 0 and
- 1 months and 10 μg RH5.1 with 50 μg Matrix-M<sup>TM</sup> at 6 months. "High Infants DFx" (infants aged 5-17
- months with higher prior malaria exposure based on anti-parasite lysate IgG at screening) received 50 µg
- RH5.1 with 50  $\mu$ g Matrix-M<sup>TM</sup> at 0 and 1 months and 10  $\mu$ g RH5.1 with 50  $\mu$ g Matrix-M<sup>TM</sup> at 6 months.
- The main reason for participant withdrawal was consent withdrawal which was not due to adverse
- experience. Two participants died during the course of the study unrelated to study vaccination. All
- participants who received at least a single dose of RH5.1/Matrix-M<sup>TM</sup> were analyzed as part of the safety
- 727 cohort. All participants who received at least a single dose of RH5.1/Matrix-M<sup>™</sup> for whom data
- concerning immunogenicity endpoint measures were available were analyzed as part of the
- immunogenicity cohort. Two participants in the "High Infants DFx" group were recruited in error at
- below the "high" exposure threshold and are included in the immunogenicity analysis as indicated in
- subsequent figures.
- 732

### 733 Figure 2: Solicited adverse events (AEs) following vaccination.

Participants (or their carers) were asked about the presence of systemic and local AEs on the day of each
study vaccination and for the following 7 days. The maximum severity reported by each participant for

Silk SE *et al*.

- each AE after each study vaccination is shown. 10M = monthly vaccination regimen; DFx = delayed
  fractional regimen; 10D = delayed regimen.
- 738

### 739 Figure 3. Serum antibody response to vaccination.

- 740 Median and individual anti-RH5.1 serum total IgG responses as measured by ELISA are shown at 14
- days post-second vaccination (V2+14), day of third vaccination (V3), and 14, 309 and 674 days post-third
- 742 vaccination (V3+14 / 309 / 674) for (A) "Adults 10M" (N=5) and "Adults DFx" (N=6), and (B) "Infants
- 743 10M" (N=10-12), "Infants 10D" (N=11-12) and "Infants DFx" (N=8-12). "Infants 10M" and "Infants
- 10D" data were pooled at V2+14 due to identical immunization and dosing regimen at this time-point.
- 745 The red dotted line indicates the protective threshold associated with protection against *P. falciparum*
- blood-stage challenge in RH5-vaccinated *Aotus* monkeys (~300 µg/mL)<sup>8</sup>. (C) ELISA data shown for the
- 747 "Infants DFx" (N=8-12) and "High Infants DFx" (N=10-11) groups. Open symbols indicate N=2
- participants who did not meet high pre-exposure threshold. Group kinetic responses are shown in Figure
- 749 S6C. Analyses used Mann-Whitney test between dosing regimens within age groups only, \*P < 0.05, \*\*P
- 750 < 0.01; and Kruskal-Wallis with Dunn's multiple comparison test for V3, V3+14, V3+309 and V3+674 in</p>

751 (B) \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, \*\*\*P < 0.001.

752

#### 753 **Figure 4. Functional GIA induced by RH5 vaccination.**

*In vitro* GIA of total IgG purified from serum was assessed against 3D7 clone *P. falciparum* parasites.
 Median and individual values are shown for each group at (A) Baseline (day 0) at 10 mg/mL total IgG;

- (B) 14 days post-third vaccination (V3+14) at 10 mg/mL total IgG; and (C) V3+14 at 2.5 mg/mL total
- 757 IgG ("Adults 10M" N=4-6; "Adults DFx" N=6; "Infants 10M" N=12; "Infants 10D" N=11; "Infants
- 758 DFx" N=12). Open circle datapoint in (C) is arbitrarily set at 0 % GIA and for the sample not titrated in
- the assay. Red dashed line in (C) indicates threshold of 60 % GIA associated with protective outcome in

Silk SE et al.

760	RH5-vaccinated and <i>P. falciparum</i> challenged <i>Aotus</i> monkeys <sup>8</sup> . Analysis between infant dosing regimens
761	by Kruskal-Wallis with Dunn's multiple comparison test, $*P < 0.05$ , $**P < 0.01$ . ( <b>D</b> ) GIA of samples at
762	baseline and V3+14 tested at 10 mg/mL and 2.5 mg/mL total IgG from the "Infants DFx" (N=12) and
763	"High Infants DFx" (N=10-12) cohorts. Open symbols indicate N=2 participants who did not meet the
764	high pre-exposure threshold. Analysis used Mann-Whitney test to compare between the two groups; ns =
765	not significant. (E) V3+14 samples were titrated in the GIA assay using a 2-fold dilution series starting at
766	10 mg/mL. Relationship between GIA data from the dilution series and the concentration of anti-RH5.1-
767	specific IgG used in the assay as measured by ELISA in the total IgG is shown. Non-linear regression
768	curves (constrained to >0 % and <100 % GIA) are shown for each group. The $EC_{50}$ (concentration of anti-
769	RH5.1 polyclonal IgG that gives 50 % GIA) was calculated (dashed line represents 50% GIA) using data

points pooled across all groups ( $r^2 = 0.95$ , N=487).









- Infants 10M
- Infants 10D
- Infants DFx

